Can Europe step in if U.S. drug pricing cracks? A Perspective
Fragmented systems limit Europe’s launch appeal — but targeted, regional actions could strengthen its position, help preserve access to innovation
Investors breathed a sigh of relief when last week’s MFN executive order appeared too vague to advance. But make no mistake: drug price controls remain a U.S. political priority. Even if this attempt stalls, efforts to curb prices — through international benchmarking or other means — are likely to continue.
The risk of a diminished U.S. market hovered over conversations at BioCentury’s 25th Bio€quity Europe conference last week in Bruges. Yet, the vibe was mostly upbeat as attendees focused on constructive paths forward for Europe. Up for debate was whether the region can position itself to capture a larger share of first drug approvals, with earlier access for European patients and injection of energy into Europe’s biotech sector the hopeful outcomes. ...